Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia.
about
Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis.Minimal residual disease in acute myeloid leukaemiaImpact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.A chromatic explosion: the development and future of multiparameter flow cytometry.The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia.Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation.Minimal residual disease as a predictive factor for relapse after allogeneic hematopoietic stem cell transplant in adult patients with acute myeloid leukemia in first and second complete remission.Does a diagnosis of myelogenous leukemia require 20% marrow myeloblasts, and does <5% marrow myeloblasts represent a remission? The history and ambiguity of arbitrary diagnostic boundaries in the understanding of myelodysplasia.Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic SyndromeRole of flow cytometry in myelodysplastic syndromes: diagnosis, classification, prognosis and response assessment.Immunophenotyping by Multiparameter Flow Cytometry.Parthenolide Induces Apoptosis in Committed Progenitor AML Cell line U937 via Reduction in Osteopontin.Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol.Significance of CD71 expression by flow cytometry in diagnosis of acute leukemia.The Use of Flow Cytometry in Myelodysplastic Syndromes: A Review.Immunophenotypes of Chronic Myelomonocytic Leukemia (CMML) Subtypes by Flow Cytometry: A Comparison of CMML-1 vs CMML-2, Myeloproliferative vs Dysplastic, De Novo vs Therapy-Related, and CMML-Specific Cytogenetic Risk Subtypes.Methods for the identification, characterization and banking of human DPSCs: current strategies and perspectives.
P2860
Q33868700-D71FF8DE-24FC-415C-9552-B31CB556495FQ34179265-50AEFB85-B5CF-4108-A125-F9C68D3C2741Q34877613-E0C0A3F7-4B84-416C-9B53-2F9E46212CCFQ34919897-251FE5EE-8DCE-45AD-BF9D-45A35D662D7DQ36153480-3F1821F7-9060-4143-9048-F4DCCAB1CAD9Q36505822-66A260E9-304A-4A88-86FD-6EA3A691854DQ37016999-3A916C2E-1D9E-4971-8DE4-806843C709DEQ37191355-B93E2488-3DB4-48B9-BA67-FB229F855E9FQ37207443-77F064B5-FFC6-4C76-AD66-12B1DE6DD27DQ38117677-438C132D-4317-466D-AB36-34EB6BED4EEAQ38666234-3F2879BB-8C16-42B5-93A1-94B028C10482Q38751301-072F6801-FBE7-436A-9BCA-890857882972Q39968886-E48AF282-DF56-4A89-8FBC-20D699EFB1D4Q40316983-E37710DD-E225-4A98-950C-E4DB9EA1DAD3Q46351056-8AF4BB45-A68A-4181-AA94-296F0E49D830Q47145316-FCA79B66-6130-4360-ADA2-126301CA8829Q53066596-377E7E79-D66D-46D2-B5D3-EECA796D4003Q53268341-27F96A75-8F07-4E85-A2BB-B74E1793B1AE
P2860
Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Myeloid malignancies: myelodys ...... s, and acute myeloid leukemia.
@en
type
label
Myeloid malignancies: myelodys ...... s, and acute myeloid leukemia.
@en
prefLabel
Myeloid malignancies: myelodys ...... s, and acute myeloid leukemia.
@en
P1476
Myeloid malignancies: myelodys ...... s, and acute myeloid leukemia.
@en
P2093
Brent L Wood
P304
551-75, vii
P356
10.1016/J.CLL.2007.05.006
P577
2007-09-01T00:00:00Z